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Abstract 
Background: Number of diabetic patients under public primary care in Hong Kong rose from 150,157 (2009) to 
173,015 (2013). This study aimed to track the 5-year change of their outcomes and care standard after the introduc-
tion of quality enhancement programmes.
Methods: Longitudinal study was conducted on a group of diabetic patients who received continuous care under 
public primary care between 2009 and 2013. Socio-demographic and clinical data was retrieved from central data-
base. The standard of care in terms of proportion of patients achieving haemoglobin A1c (HbA1c), systolic and 
diastolic blood pressure (SBP and DBP), and low density lipoprotein-cholesterol (LDL-C) target levels, mean param-
eter changes, and 5-year cumulative incidence of major complications were assessed. Outcomes between 2009 and 
2013 were compared by McNemar’s test for proportion of patients treated to targets and paired t-test for continuous 
outcome parameters.
Results: A group of 127,977 diabetic patients who had continuous follow-up between 2009 and 2013 were assessed. 
A significantly higher proportions of patients achieving targets of HbA1c (<7 %), SBP (<130 mmHg), DBP (<80 mmHg), 
LDL-C (<2.6 mmol/L), triglyceride (<1.7 mmol/L), and high density lipoprotein-cholesterol (>1.0 or 1.3 mmol/L) were 
observed (p < 0.001). There was a significant drop in the mean values of HbA1c (7.2–7.0 %), SBP (136.9–131.3 mmHg), 
DBP (75.4–72.1 mmHg), LDL-C (3.1–2.4 mmol/L), triglyceride (1.7–1.4 mmol/L), and body mass index (25.6–25.3 kg/
m2). More patients (0.6 % raised to 3.5 %) used insulin in addition to their oral anti-diabetic drugs for their manage-
ment, and a significant boost (from 9.0 to 55.0 %) was on statin use. 5-year cumulative incidence of any major diabetic 
complication was 6.2 %.
Conclusions: Standard of public primary care for diabetic patients enhanced from 2009 to 2013, as reflected by the 
improvement in outcomes of care. It could be related to the implementation of the territory-wide quality enhance-
ment programmes in all public primary care clinics since 2009, with coverage increasing from 3.1 % (2009) to 81.9 % 
(2013).
Clinical trial number and registry: NCT02034695, ClinicalTrials.gov
Keywords: Diabetes mellitus, Primary care, Health service, Chinese, Population-based
© 2015 Fung et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  cfsc@hku.hk 
Department of Family Medicine and Primary Care, The University of Hong 
Kong, 3/F Ap Lei Chau Clinic, 161 Main Street, Ap Lei Chau, Hong Kong
Page 2 of 11Fung et al. Diabetol Metab Syndr  (2015) 7:79 
Background
Diabetes mellitus (DM) is a significant major chronic dis-
ease and it was estimated 1 in 12 people was affected by 
diabetes in the world [1]. The World Health Organization 
projected that by 2030, diabetes would be the seventh 
most common cause of death in the world [2]. A good 
control of DM is crucial because DM is closely linked 
to various complications, ranging from different cardio-
vascular diseases (including myocardial infarction, cer-
ebrovascular diseases, etc.) to microvascular diseases like 
diabetic retinopathy [including sight-threatening diabetic 
retinopathy (STDR)] and diabetic nephropathy [includ-
ing end stage renal failure (ESRF)]. Health spending on 
diabetes increased to 548 billion, accounting for 10.8 % of 
total health expenditure worldwide in 2013 [1]. Patients 
with DM complications significantly increased medical 
costs compared with patients without DM complications 
[3]. A huge number of diabetic patients and substantial 
public health burden will be further exacerbated by the 
rapidly ageing population in the world. To prevent dia-
betic complications, many overseas national professional 
associations have developed guidelines on the manage-
ment of diabetes [4–7]. Similar initiative was also called 
for to assure the management and quality of care of dia-
betes for the population in Hong Kong (HK).
Hong Kong, being an international city with many peo-
ple leading a Western lifestyle, hosted a significant and 
increasing number of diabetic patients in recent years. 
Local data showed that the prevalence of diabetic mel-
litus was 9.92 % (diagnosed plus undiagnosed) [1]. Total 
annual costs for diagnosed Type 2 DM patients in HK 
were estimated to take up 6.4 % of the total expenditure 
of the public healthcare sector in 2004 [8]. In order to 
enhance the quality of care of patients with chronic dis-
eases like diabetes mellitus under the public primary care 
setting, various territory-wide quality enhancement pro-
grammes have been introduced in phases, including Risk 
Assessment and Management Programme-Diabetes Mel-
litus (RAMP-DM), Patient Empowerment Programme, 
Nurse Allied Health Clinic, Call Centre, etc. RAMP-DM 
is exclusively for diabetic patients, and it has started 
implementation since 2009, with its coverage raised 
from 3.1 % in 2009 to 81.9 % in 2013 of all the diabetic 
patients under the care of public primary healthcare sec-
tor. The details of the RAMP-DM had been illustrated 
in our previous protocol paper [9]. Diabetic patients are 
encouraged to live and work in the community, and pri-
mary care approach of community-based care are appro-
priate to majority of the diabetic patients who do not 
require specialist care [10, 11]. In spite of this predomi-
nant chronic disease in the society, there were no formal 
standardized guidelines or recommendations provided to 
the local health care doctors as a local reference on how 
their diabetic patients should be managed before 2010. 
In 2010, the HK Reference Framework for Diabetes Care 
for Adults in Primary Care Setting was published and 
served as a population-wide guideline for strengthening 
community-based primary care, focusing on prevention, 
and quality improvement in the management of DM [12]. 
Previous studies demonstrated that healthcare systems 
relying more on primary care rather than specialist care 
produce better population health outcomes, enhance 
continuity and access to health care [13–17]. Neverthe-
less, currently, limited primary care and population-
based data on patient’s clinical and complications profile 
of diabetic patients was available to identify the needs of 
the practices and population. Continued territory-wide 
evaluation of diabetes control in the population is vital to 
sustain improvement in diabetic care and inform health 
policy makers in service planning and resource allocation 
to prevent the development of complications and pre-
serve quality of life of the diabetic population.
The aims of this study were to track the recent 5-year 
changing diabetic care by reviewing the clinical and com-
plication profile, to evaluate the trend in risk-factor con-
trol, and to identify the needs and gaps of the practices 
among diabetic patients based on the 5-year population-
based data from 2009 to 2013.
Methods
Study design
A territory-wide longitudinal study was conducted on 
a group of diabetic patients who received continuous 
care under public primary care between 2009 and 2013. 
Patients with a clinical diagnosis of Type 1 or Type 2 DM, 
and receiving primary care in general outpatient clinics 
of Hospital Authority (HA) between 1 January 2009 and 
31 December 2009 were included in the study. DM was 
identified with the International Classification of Primary 
Care-2 (ICPC-2) code of ‘T89’ or ‘T90’ through the Clini-
cal Management System (CMS) database of HA. Diabetic 
patients who did not have records of follow-up between 
1 January 2013 and 31 December 2013 were excluded for 
analysis. Relevant socio-demographic and clinical data 
was retrieved from central CMS of HA database. Due to 
an enormous subsidized public healthcare policy in HK, 
the majority of diabetic patients are managed in pub-
lic outpatient clinics or hospitals governed by the HA, 
which provides 90 % of in-patients service in HK [18, 19].
Ethics approval of this study was granted by the Insti-
tutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West (UW 10-369), Hong 
Kong East (HKEC-2010-093), Kowloon East and Kow-
loon Central (KC/KE-10-0210/ER-3), Kowloon West 
(KW/EX/10-317 (34-04)), New Territories East (CRE-
2010.543), and New Territories West clusters (NTWC/
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CREC/1091/12) and clinical trial registry (NCT02034695, 
ClinicalTrials.gov).
Social‑demographics and clinical profile
The medical records of hospital admissions and out-
patient clinic attendance in all public hospitals and 
outpatient clinics were retrieved from the administra-
tive database of HA. Socio-demographics of patients 
included sex, age, smoking status, alcohol drinking habit 
and duration of diabetes. Clinical variables included 
body mass index (BMI), waist–hip ratio, hemoglobin A1c 
(HbA1c), systolic and diastolic blood pressure (SBP and 
DBP), lipid profile [low density lipoprotein-cholesterol 
(LDL-C), high density lipoprotein-cholesterol (HDL-C), 
total cholesterol (TC), TC/HDL-C ratio and triglyceride] 
and urine albumin-to-creatinine ratio (ACR). Treatment 
modalities included the use of antidiabetic drugs (e.g. 
metformin, sulphonylurea, gliptin and insulin, etc.), anti-
hypertensive drugs [e.g. angiotensin converting enzyme 
inhibitor (ACEI) or angiotensin receptor blocker (ARB), 
β-blocker, calcium channel blocker (CCB), diuretic], 
lipid-lowering agents (Statin and fibrate) and aspirin. The 
latest available record before and closest to 31 December 
2009 and 31 December 2013 for each patient was used to 
represent the data of 2009 and 2013 respectively.
Diabetic complications identification and definition
The medical records documented the diagnosis coding 
system of ICPC-2 and International Classification of Dis-
eases, Ninth Edition, Clinical Modification (ICD-9-CM) 
for each outpatient visit and hospital admission respec-
tively. In this study, Coronary Heart Disease (CHD) 
(ischaemic heart disease, myocardial infarction, coro-
nary death or sudden death) was defined as earliest date 
of diagnosis with either ICPC-2 of K74 to K76 or ICD-
9-CM of 410.x, 411.x to 414.x, 798.x. Stroke (fatal and 
non-fatal stroke) was defined as earliest date of diagnosis 
with either ICPC-2 of K89 to K91 or ICD-9-CM of 430.x 
to 438.x. Heart failure was defined as earliest date of diag-
nosis with either ICPC-2 of K77 or ICD-9-CM of 428.x. 
Cardiovascular disease (CVD) is defined as the presence 
of any of CHD, heart failure and stroke ICPC-2 or ICD-
9-CM codes as above. STDR (proliferative diabetic retin-
opathy, retinal haemorrhage, maculopathy and blindness) 
was defined as earliest date of diagnosis with ICD-9-CM 
of 362.02, 362.07, 362.31 362.81 and 369.x and ESRF was 
defined as earliest date of diagnosis with ICD-9-CM of 
250.3x, 585.x, 586.x.
Measure outcomes
Primary outcome measures were the change in propor-
tions of patients achieving treatment targets, namely, 
HbA1c <7 %, SBP <130 mmHg, DBP <80 mmHg, LDL-C 
<2.6 mmol/L, TG <1.7 mmol/L, and HDL-C >1 mmol/L 
(male) or >1.3 mmol/L (female), etc. Secondary outcome 
measures were the changes in these clinical variables, 
drug use pattern, and the 5-year cumulative incidence of 
major DM complications.
Data analysis
Descriptive statistics were used to show patient’s socio-
demographics, clinical variables, and drug usage pattern. 
Outcomes between 2009 and 2013 were compared by 
McNemar’s test for proportion of patients treated to tar-
gets and paired t-test for mean level of continuous out-
come parameters. For the 5-year cumulative incidence of 
major DM complications, patients without correspond-
ing DM complications at baseline were included into the 
calculation.
Results
The flow of diabetic subjects in the study was sum-
marized in Fig.  1. A total of 150,157 diabetic patients 
received public primary care at 2009. Among these 
patients, 127,977 (85.2  %) subjects were found continu-
ously receiving public primary care at 2013 and their data 
was included for analysis in this study.
The data completion rates for socio-demographic 
and clinical parameters in 2009 and 2013 were shown 
in Additional file  1. Clinical data (e.g., BMI, waist–hip 
ratio, HbA1c, SBP, DBP, full lipid profile and urine ACR, 
etc.,) completion rate improved significantly. Table 1 and 
Additional file  2 showed the socio-demographics of the 
127,977 DM patients in 2009. Mean age was 64.0. Female 
was around 10 % more than male.
Tables 2, 3 and Figs. 2, 3 compared their clinical vari-
ables at 2009 and 2013. A significant increase of pro-
portions of patients achieving treatment targets, 
including HbA1c <7  % (increased from 47.5 to 56.5  %), 
SBP <130  mmHg (increased from 47.5 to 56.5  %), DBP 
<80  mmHg (increased from 65.7 to 77.5  %), LDL-C 
<2.6  mmol/L (increased from 25.9 to 65.6  %), TG 
<1.7 mmol/L (increased from 61.6 to 74.9 %), and HDL-C 
>1.0 mmol/L (male) or >1.3 mmol/L (female) (increased 
from 47.0 to 60.6  %) were observed (p  <  0.001). Mean 
values of clinical variables also dropped significantly 
including HbA1c (from 7.2 to 7.0 %), SBP (from 136.9 to 
131.3  mmHg), DBP (from 75.4 to 72.1  mmHg), LDL-C 
(from 3.1 to 2.4 mmol/L), TG (from 1.7 to 1.4 mmol/L), 
and BMI (from 25.6 to 25.3 kg/m2). On the other hand, 
more proportion of diabetic patients had central obesity 
(raised from 77.1 to 81.3  %) and increased ACR (raised 
from 23.0 to 26.3 %).  
Table 4 showed the change of drug use pattern between 
2009 and 2013. More patients were prescribed oral anti-
diabetic medications, with metformin being the most 
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commonly prescribed drug (raised from 71.1 to 80.4 %). 
A lower proportion of patients used sulphonylurea group 
of drugs and 1.2 % of patients started using gliptin. More 
patients (raised from 0.6 to 3.5 %) used insulin in addition 
to their oral anti-diabetic drugs for their management, 
and a significant boost (from 9.0 to 55.0 %) on statin use 
was observed.
Table  5 illustrated the 5-year cumulative incidence 
of major DM complications in the period from 2009 to 
2013. A total of 8,625, 572 and 155 patients with CVD, 
STDR, and ESRD, respectively, at baseline were excluded 
for the calculation of 5-year cumulative incidences of 
corresponding events. Hence, the 5-year cumulative 
incidences for CVD, STDR, and ESRD were 5.1, 0.7, and 
0.8 %, respectively. 
Discussion
This article is by far the latest and largest territory-wide 
review of the status and control of health parameters of 
diabetic patients, with a follow-up of a 5-year period. 
From 2009 to 2013, the quality of care had been enhanced 
both in terms of the structure, like documentation of 
the patients’ clinical data, as well as the process, like the 
annual checking of diabetic patients’ clinical variables. 
This undoubtedly raised the standard of care being deliv-
ered to patients with chronic diseases like diabetes mel-
litus as previous records were made accessible and thus 
continuity of care was facilitated. Having all these clinical 
variables checked and documented allows regular system-
atic audit of how these patients progress further on.
The standard of care for diabetic patients under pri-
mary care in HK, as reflected by the control of HbA1c, 
BP and LDL-C, is comparable with that achieved in 
the developed countries such as UK and US [20, 21]. 
Improvement in coverage of annual checking of key clini-
cal variables may attribute to the more regular monitor-
ing, which allowed early intervention, such as medication 
intervention. This as a result led to the improvement in 
the proportions of reaching treatment targets.
All these changes were paralleled with the implement 
of the territory-wide quality enhancement programmes 
since 2009. Amongst these programmes, the RAMP-DM 
coverage rate raised from 3.1 % (2009) to 81.9 % (2013) 
of all the diabetic patients under public primary care. 
The details of the RAMP-DM had been illustrated in our 
previous protocol paper [9]. One of the key impacts was 
the advocating use of insulin and statin for the better 
control of diabetes mellitus and the associated hyperlipi-
demia at the primary care level. The significant increase 
of patients using insulin in addition to oral anti-diabetic 
drug, together with the increased proportion of patients 
using metformin and newer class of oral anti-diabetic 
drugs like gliptin class are closely linked to the reduc-
tion of mean HbA1c from 7.2 to 7.0 % in 5 years, and the 
increased proportion of patients having HbA1c <7  %. 
Based on the UK prospective diabetes study [22], every 
1 % reduction in mean HbA1c was associated with reduc-
tions in relative risk of 14  % for all-cause mortality and 
9.9 % for CHD. Therefore the 0.2 % reduction of HbA1c 
shown in our study has the potential impact of having a 
Fig. 1 Flow chart of subjects. The flow chart showed the participant enrollment in each stage. DM diabetes melltius
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reduction of relative risk of 2.8 % for all-cause mortality 
and 2.0 % for CHD.
Most Chinese patients refused insulin injection as they 
have the misconception that insulin injection was pain-
ful and they had needle phobia, especially in those who 
have never started insulin [23]. Education on insulin 
usage helps patients clear these kinds of misconception 
and allows them to accept the daily injection of insulin 
and improve glucose control [24]. Coupling the drop 
in mean HbA1c was the drop in proportion of diabetic 
patients solely on diet or lifestyle modification alone. 
This was in-line to the argument that metformin should 
be initiated early in the management of diabetic patients. 
Metformin is the first-line oral anti-diabetic drug and 
recently there were some studies showing its benefit on 
reducing cardiovascular complications, in addition to 
that of lowering HbA1c [25, 26]. With the increased pro-
portion of our patients using metformin, we will study 
the link between metformin use in Chinese patients and 
cardiovascular risk. Newer classes of oral anti-diabetic 
drugs like Dipeptidyl Peptidase-4 Inhibitors class were 
relatively expensive and patients need to self-purchase 
these newer drugs in most of the circumstances, which 
lowered the popularity of such drug usage. As aging pop-
ulation and the associated pancreatic function deteriora-
tion is foreseen, the effectiveness of these newer class of 
anti-diabetic drugs has to be studied. The dramatic boost 
of statin use explained the drop of mean LDL-C from 3.1 
to 2.4 mmol/L and the increased proportion of patients 
achieving LDL-C target of <2.6  mmol/L. A previous 
study showed that an increment of 1 mmol/L in LDL-C 
concentration correlates with a 1.57 increased relative 
Table 1 Socio-demographic of  the 127,977 diabetic sub-
jects at 2009
DM diabetes mellitus, BMI body mass index, HbA1c haemoglobin A1c, SBP 
systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density 
lipoprotein-cholesterol, TC total cholesterol, HDL-C high-density lipoprotein-
cholesterol, ACR albumin/creatinine ratio
Subjects (N = 127,977)
Socio-demographic, (mean ± SD)
 Age, year 64.0 ± 11.2
  <65 52.5 %
  ≥65 47.5 %
 Sex
  Female 55.8 %
  Male 44.2 %
 Smoking status
  Non-smoker 77.7 %
  Current smoker 5.6 %
  Ex-smoker 16.7 %
 Drinking status
  Non-drinker 76.4 %
  Current drinker 2.8 %
  Social drinker 12.9 %
  Ex-drinker 7.8 %
 Education level
  No formal education/primary 20.1 %
  Primary 39.6 %
  Secondary/tertiary 35.6 %
  Tertiary 4.7 %
 Duration of DM, year 7.1 ± 6.0
  ≤5 years 41.7 %
  5–10 years 30.0 %
  >10 years 28.3 %
Table 2 Change in levels of clinical variables among 127,977 diabetic subjects between 2009 and 2013
DM diabetes mellitus, BMI body mass index, HbA1c haemoglobin A1c, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density lipoprotein-
cholesterol, TC total cholesterol, HDL-C high-density lipoprotein-cholesterol, ACR albumin/creatinine ratio
* Significant difference (P < 0.05) by paired t-test
2009 2013 Paired difference P‑value
Clinical parameters (mean ± SD)
 BMI, kg/m2 25.6 ± 3.9 25.3 ± 3.9 −0.3 ± 1.8 (n = 71,224) <0.001*
 Waist–hip ratio 0.9 ± 0.2 0.9 ± 0.1 0.01 ± 0.2 (n = 47,714) <0.001*
 HbA1c,  % 7.2 ± 1.2 7.0 ± 1.1 −0.2 ± 1.3 (n = 113,066) <0.001*
 Systolic blood pressure, mmHg 136.9 ± 16.9 131.3 ± 15.0 −5.6 ± 19.8 (n = 126,863) <0.001*
 Diastolic blood pressure, mmHg 75.4 ± 10.2 72.1 ± 10.0 −3.3 ± 11.0 (n = 126,863) <0.001*
 LDL-C, mmol/L 3.1 ± 0.8 2.4 ± 0.7 −0.7 ± 0.9 (n = 72,040) <0.001*
 Triglyceride, mmol/L 1.7 ± 1.1 1.4 ± 0.8 −0.3 ± 1.0 (n = 73,631) <0.001*
 Total cholesterol, mmol/L 5.1 ± 0.9 4.3 ± 0.8 −0.7 ± 1.0 (n = 74,574) <0.001*
 HDL-C, mmol/L 1.2 ± 0.3 1.3 ± 0.4 0.1 ± 0.3 (n = 73,406) <0.001*
 TC/HDL-C ratio 4.4 ± 1.3 3.5 ± 1.0 −0.9 ± 1.2 (n = 73,294) <0.001*
 Urine ACR, mg/mmol 4.7 ± 18.6 7.9 ± 35.1 3.2 ± 33.1 (n = 28,250) <0.001*
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Fig. 2 Distribution of clinical variables in 127,977 diabetic subjects between 2009 and 2013. The distribution of clinical variables including BMI, 
WHR, HbA1c, SBP, DBP, LDL-C among 127,977 diabetic subjects were denominated at 2009 (white area with black borders) and 2013 (blue area). The 
red line indicates the target standard of the clinical variables. BMI body mass index, WHR waist–hip ratio, HbA1c haemoglobin A1c, SBP systolic blood 
pressure, DBP diastolic blood pressure, LDL-C low-density lipoprotein-cholesterol
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risk of coronary heart disease [27], which equated to a 
36 % relative risk of CHD for a decrement of 1 mmol/L 
in LDL-C. Therefore the 0.7 mmol/L reduction of LDL-C 
shown in our study has the potential impact of having 
a reduction of relative risk of 25.2  % for CHD. Propor-
tions of diabetic patients with hyperlipidemia being pre-
scribed statin raised tremendously from 15.8 % in 2009 to 
56.9 % in 2013. However there was still around one-third 
(37.5  %) of patients not achieving target LDL-C with 
around 40 % of diabetic patients with hyperlipidemia still 
not being given statin in 2013. The underlying reasons 
needed to be further studied. On the contrary, the num-
ber of patients using fibrate was reduced but the overall 
control of triglyceride improved with dropping of mean 
TG from 1.7 to 1.4 mmol/L, and more patients achieving 
target of TG <1.7 mmol/L. One of the hypotheses may be 
the partial triglyceride lowering effect of statin which was 
prescribed extensively [28, 29], or the associated reduc-
tion in BMI [30, 31].
Both mean SBP and DBP showed significant drop of 5 
and 3 mmHg, respectively, and more patients achieving 
target SBP of <130 mmHg and DBP of <80 mmHg. Previ-
ous literature demonstrated that each 10 mmHg decrease 
in mean SBP was associated with a relative risk of 12 % 
for all-cause mortality and 13  % for CHD [32]. Hence, 
the 5  mmHg reduction of SBP shown in our study has 
the potential impact of having a reduction of relative risk 
of 6.0 % for all-cause mortality and 6.5 % for CHD. Simi-
larly, this may be explained by the increased use of anti-
hypertensive medications within these 5  years. It was 
noteworthy that calcium channel blocker was the most 
prevalent anti-hypertensive drugs used in our diabetic 
patients (over 70  %), while ACEI or ARB ranked only 
the second (just above 50  %). ACEI or ARB, due to its 
renal protective effect, are supposed to be beneficial for 
diabetic patients and are preferred. Proportions of dia-
betic patients using ACEI or ARB were static at around 
59.4–58.3  % between 2009 and 2013. The under use of 
Fig. 3 Distribution of clinical variables in 127,977 diabetic subjects between 2009 and 2013. The distribution of clinical variables including HDL-C, 
TC, TC/HDL-C ratio and Triglyceride among 127,977 diabetic subjects were denominated at 2009 (white area with black borders) and 2013 (blue area). 
The red line indicates the target standard of the clinical variables. HDL-C high-density lipoprotein-cholesterol, TC total cholesterol
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ACEI or ARB was also reflected by the elevation of mean 
urine ACR from 4.7 mg/mmol in 2009 to 7.9 mg/mmol in 
2013, and the associated increased proportion of patients 
having urine ACR >2.5  mg/mmol (male) and >3.5  mg/
mmol (female). Chinese patients had about 50 % chance 
of suffering dry cough on ACEI [33, 34]. The alternative 
use of ARB could help solve the problem while offering 
renal protective effect [35, 36], despite the cost of ARB 
over ACEI is an issue. Appropriate prescription of ARB 
in diabetic patients should be advocated.
In spite of the improvement in the overall mean HbA1c 
and full lipid profile, the mean BMI dropped only 0.3 kg/
m2 after 5  years, and the proportion of patients hav-
ing central obesity raised from 77.1 to 81.3  %. This 
suggested that body weight and body fitness manage-
ment may not be feasible if exercise was not taken into 
account. The impact of exercise should be evaluated on 
the control of diabetes mellitus, SBP, DBP, and full lipid 
profile, and should be integrated to the management 
plan of diabetic patients [37, 38]. Similarly, despite the 
significant improvement in HbA1c, SBP, DBP, and full 
lipid profile, the 5-year cumulative incidence of major 
Table 3 Change in  proportions of  patients achieving 
treatment targets among  127,977 diabetic subjects 
between 2009 and 2013
DM diabetes mellitus, BMI body mass index, HbA1c haemoglobin A1c, SBP 
systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density 
lipoprotein-cholesterol, TC total cholesterol, HDL-C high-density lipoprotein-
cholesterol, ACR albumin/creatinine ratio
* Significant difference (P < 0.05) by McNemar’s test
2009 (%) 2013 (%) P‑value
Clinical parameters (mean ± SD)
 BMI, kg/m2 <0.001*
  <23 kg/m2 25.3 28.5
  ≥23 and <27.5 kg/m2 47.8 46.5
  ≥27.5 and <30 kg/m2 15.2 14.0
  ≥30 kg/m2 11.8 11.0
 Waist hip ratio <0.001*
  ≤0.9 male; ≤0.85 female 22.9 18.7
  >0.9 male; >0.85 female 77.1 81.3
 HbA1c, % <0.001*
  <7 % 47.5 56.5
  ≥7 % 52.5 43.5
 Systolic blood pressure, mmHg <0.001*
  <130 mmHg 47.5 56.5
  ≥130 mmHg 52.5 43.5
 Diastolic blood pressure, mmHg <0.001*
  <80 mmHg 65.7 77.5
  ≥80 mmHg 34.3 22.5
 LDL-C, mmol/L <0.001*
  <2.6 mmol/L 25.9 65.6
  ≥2.6 mmol/L 74.1 34.4
 Triglyceride, mmol/L <0.001*
  <1.7 mmol/L 61.6 74.9
  ≥1.7 mmol/L 38.4 25.1
 Total cholesterol, mmol/L <0.001*
  <4.5 mmol/L 26.4 61.0
  ≥4.5 mmol/L 73.6 39.0
 HDL-C, mmol/L <0.001*
  ≤1.0 mmol/L male; ≤1.3 mmol/L 
female
53.0 39.4
  >1.0 mmol/L male; >1.3 mmol/L 
female
47.0 60.6
 TC/HDL-C ratio <0.001*
  <4.5 55.7 85.4
  ≥4.5 44.3 14.6
 Urine ACR, mg/mmol <0.001*
  ≤2.5 mg/mmol man; ≤3.5 mg/mmol 
female
77.0 73.7
  >2.5 mg/mmol man; >3.5 mg/mmol 
female
23.0 26.3
Table 4 Comparison of  the drug use pattern of  the 
127,977 diabetic subjects between 2009 and 2013
Others included Acarbose, Glucagon-like peptide-1 agonist, Meglitinides
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, 
CCB calcium channel blocker
a The denominator was diabetic patients with hypertension (93,234 and 106,361 
at 2009 and 2013, respectively)
b The bracket shows the proportion of diabetic patients with hyperlipidemia 
who are put on statin
c The bracket shows the proportion of diabetic patients with confirmed CVD 
who were put on aspirin
Type of therapy 2009 (%) 2013 (%)
Lifestyle modification only 15.7 10.2
Oral anti-diabetic drug only 83.7 86.3
Insulin only 0.2 0.5
Oral anti-diabetic drug + insulin 0.5 3.0
Anti-diabetic drugs
 Metformin 71.1 80.4
 Sulphonylurea 57.0 60.4
 Gliptin 0.0 1.2
 Insulin 0.6 3.5
 Others 0.1 0.1
Anti-hypertensive drugsa
 None 2.5 3.6
 ACEI or ARB 59.4 58.3
 β-blocker 39.2 35.5
 CCB 73.9 71.0
 Diuretic 11.8 10.7
 Other anti-hypertensive drugs 15.1 13.8
Lipid lowering drugs
 Statin 9.0 (15.8 %)b 55.0 (56.9 %)b
 Fibrate 4.6 2.5
Aspirin 8.8 (75.8 %)c 14.0 (75.7 %)c
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DM complications including various CVD were shown 
higher than that of the general population in Asia [39]. 
Previous studies also showed that diabetic patients were 
about 2–4 times more likely to have CVD than non-
diabetic patients [40, 41]. This difference was expected 
because hypertension, hyperlipidemia, hyperglycaemic 
and obesity, those contribute to the risk for developing 
CVD, occur more frequently in patient with T2DM com-
pared to general population [42]. In this study, there were 
a total of 6117 new CVD events amongst those without 
CVD events at baseline in 2009 after 5 years. This may be 
related to the concurrent elevation of urine microalbu-
min level, which was shown to be a significant prognostic 
factor for various DM complications [43]. Use of aspirin 
was raised from 8.8 % in 2009 to 14.0 % in 2013, and the 
majority of those patients having complications were put 
on aspirin. Aspirin usage as a primary preventive meas-
ure in diabetic patients was unknown in our locality and 
worth exploration. Also, patient’s self-management and 
adherence of therapy play essential role in achieving the 
goals of diabetes care and thus further studies is needed 
to identify and evaluate such characteristics of patients.
Strengths and limitations
The strengths of this study included the territory-wide 
coverage and tracking for 5 years of all diabetic patients 
under the care of public primary care across the whole 
territory of HK. The huge number of diabetic patients 
being followed up and information being collected could 
comprehensively reflect the quality of care delivered by 
the public primary health care system in HK. Besides, the 
follow-up period of 5  year allows revealing of subtle or 
slow progress of parameters like BMI, and complications 
of low incidence rate like ESRD, etc.
There were some limitations in this study. Firstly, only 
medical records from the public hospitals and clinics 
were being able to access to capture information of the 
diabetic patients and the DM-related complications. The 
patients and events that were under specialist care or 
in the private sector were not identified. Nevertheless, 
based on the enormous subsidized public health care 
policy in HK, there was a substantial discrepancy in med-
ical fees between public and private services, and many of 
the patients received public healthcare if they developed 
complications. Our findings were generated from a large 
scale of population-based database of the public service 
that provide care to the majority of patients with chronic 
diseases like diabetes, and a significant proportion of hos-
pital admissions for management of DM-related compli-
cations had been covered. Secondly, since data of some of 
the other quality enhancement programmes are not com-
prehensive, comparison of individual programmes was 
not feasible at this moment. Lastly, approximately 95 % of 
HK population is of Chinese descent and thus our results 
may not be generalizable to other ethnicities in Asia.
Conclusions
Our study showed the significant improvements in the 
management of DM under primary care in HK. Improve-
ment in coverage of annual checking of key clinical vari-
ables and patients’ achievement to target values may be 
attributed by the regular monitoring and early inter-
vention, including use of appropriate medications and 
the risk-stratification based multidisciplinary DM man-
agement (RAMP-DM). There is still room for further 
enhancement in the diabetes care, including body weight 
management and counseling in addition to the achieve-
ment of optimal targets. Regular evaluation of diabetes 
control is crucial to identify and sustain improvements 
in management and care of diabetic patients.
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